Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer's disease with FDG-PET.


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 11 02 2019
accepted: 11 06 2019
pubmed: 25 7 2019
medline: 21 10 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

The pattern expression score (PES), i.e., the degree to which a pathology-related pattern is present, is frequently used in FDG-brain-PET analysis and has been shown to be a powerful predictor of conversion to Alzheimer's disease (AD) in mild cognitive impairment (MCI). Since, inevitably, the PES is affected by non-pathological variability, our aim was to improve classification with the simple, yet novel approach to identify patterns of non-pathological variance in a separate control sample using principal component analysis and removing them from patient data (controls-based denoising, CODE) before calculating the PES. Multi-center FDG-PET from 220 MCI patients (64 non-converter, follow-up ≥ 4 years; 156 AD converter, time-to-conversion ≤ 4 years) were obtained from the ADNI database. Patterns of non-pathological variance were determined from 262 healthy controls. An AD pattern was calculated from AD patients and controls. We predicted AD conversion based on PES only and on PES combined with neuropsychological features and ApoE4 genotype. We compared classification performance achieved with and without CODE and with a standard machine learning approach (support vector machine). Our model predicts that CODE improves the signal-to-noise ratio of AD-PES by a factor of 1.5. PES-based prediction of AD conversion improved from AUC 0.80 to 0.88 (p= 0.001, DeLong's method), sensitivity 69 to 83%, specificity 81% to 88% and Matthews correlation coefficient (MCC) 0.45 to 0.66. Best classification (0.93 AUC) was obtained when combining the denoised PES with clinical features. CODE, applied in its basic form, significantly improved prediction of conversion based on PES. The achieved classification performance was higher than with a standard machine learning algorithm, which was trained on patients, explainable by the fact that CODE used additional information (large sample of healthy controls). We conclude that the proposed, novel method is a powerful tool for improving medical image analysis that offers a wide spectrum of biomedical applications, even beyond image analysis.

Identifiants

pubmed: 31338550
doi: 10.1007/s00259-019-04400-w
pii: 10.1007/s00259-019-04400-w
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2370-2379

Subventions

Organisme : Seventh Framework Programme (FP7/2007-2013)
ID : 603646

Références

Neurobiol Aging. 2014 Jan;35(1):143-51
pubmed: 23954175
Neuroimage. 2016 Nov 1;141:282-290
pubmed: 27453158
J Alzheimers Dis. 2017;58(2):361-371
pubmed: 28436391
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Neurology. 2010 Jan 19;74(3):201-9
pubmed: 20042704
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):334-347
pubmed: 30382303
Ann Nucl Med. 2013 Aug;27(7):600-9
pubmed: 23585159
J Nucl Med. 2016 Feb;57(2):204-7
pubmed: 26585056
Front Hum Neurosci. 2017 Feb 06;11:33
pubmed: 28220065
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1442-1448
pubmed: 29546632
J Nucl Med. 2019 Jun;60(6):837-843
pubmed: 30389825
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2042-2052
pubmed: 28664464
Nat Biotechnol. 2010 Aug;28(8):827-38
pubmed: 20676074
Neuroimage. 2011 Feb 14;54(4):2899-914
pubmed: 20969965
J Alzheimers Dis. 2018;64(4):1175-1194
pubmed: 30010119
Eur J Nucl Med Mol Imaging. 2015 Sep;42(10):1487-91
pubmed: 26067090
J Nucl Med. 2012 Apr;53(4):592-600
pubmed: 22343502
Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2191-202
pubmed: 18648805

Auteurs

Dominik Blum (D)

Institute for Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tuebingen, Germany. dominik.blum@med.uni-tuebingen.de.

Inga Liepelt-Scarfone (I)

German Center of Neurodegenerative Diseases, Eberhard Karls University, Tuebingen, Germany.
Hertie-Institute for Clinical Brain Research, Eberhard Karls University, Tuebingen, Germany.

Daniela Berg (D)

Department of Neurology, Christian-Albrechts-University, Kiel, Germany.

Thomas Gasser (T)

German Center of Neurodegenerative Diseases, Eberhard Karls University, Tuebingen, Germany.
Hertie-Institute for Clinical Brain Research, Eberhard Karls University, Tuebingen, Germany.

Christian la Fougère (C)

Institute for Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tuebingen, Germany.

Matthias Reimold (M)

Institute for Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tuebingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH